Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rivipansel - GlycoMimetics

Next Previous
X
Search
Drug Profile

Rivipansel - GlycoMimetics

Alternative Names: GM-1070; GMI-1070; PF-06460031; PF-6460031

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlycoMimetics
  • Class Anti-inflammatories; Antianaemics; Antineoplastics; Glycolipids; Naphthalenesulfonates; Pyrimidines; Small molecules
  • Mechanism of Action E-selectin inhibitors; L-selectin inhibitors; P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Vaso-occlusive crisis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological malignancies; Vaso-occlusive crisis

Most Recent Events

  • 31 Dec 2020 Discontinued - Preclinical for Haematological malignancies (Combination therapy) in USA (IV)
  • 31 Dec 2020 Discontinued - Phase-III for Vaso-occlusive-crisis (In adolescents, In children, In the elderly, In adults) in Canada (IV), USA (IV)
  • 07 Dec 2020 Efficacy data from a phase III OLE study in Vaso-occlusive-crisis released by GlycoMimetics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top